{"id":"basal-insulin-analogues","safety":{"commonSideEffects":[{"rate":"variable, dose-dependent","effect":"Hypoglycemia"},{"rate":"common","effect":"Weight gain"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"rare","effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Basal insulin analogues are engineered insulin molecules designed to have a prolonged duration of action (typically 24 hours or longer) and a relatively flat pharmacokinetic profile. They mimic the body's natural basal insulin secretion by maintaining consistent insulin levels throughout the day and night, reducing hepatic glucose production and facilitating peripheral glucose uptake. Common basal analogues from Novo Nordisk include insulin glargine (Lantus, Basaglar) and insulin degludec (Tresiba).","oneSentence":"Basal insulin analogues are long-acting insulin formulations that bind to insulin receptors to promote glucose uptake and utilization, providing steady background insulin coverage for blood glucose control.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:06.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07112339","phase":"PHASE4","title":"A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-08-15","conditions":"Diabetes Mellitus, Type 2","enrollment":586},{"nctId":"NCT04760626","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1085},{"nctId":"NCT03328845","phase":"PHASE4","title":"Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2017-01-20","conditions":"Type 1 Diabetes Mellitus","enrollment":300},{"nctId":"NCT02486341","phase":"NA","title":"Daily Glycaemic Variability in Frail or Disabled Older Patients With Diabetes Over 75 Treated With Basal Insulin","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2016-03-31","conditions":"Diabetes","enrollment":30},{"nctId":"NCT02453685","phase":"PHASE4","title":"A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":335},{"nctId":"NCT01617434","phase":"PHASE3","title":"The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":451},{"nctId":"NCT01427920","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":348},{"nctId":"NCT01068652","phase":"PHASE4","title":"Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":403},{"nctId":"NCT00873639","phase":"","title":"Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin Analogues","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":417},{"nctId":"NCT01409239","phase":"PHASE4","title":"Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Kathleen Dungan","startDate":"2011-07","conditions":"Type 2 Diabetes, Inpatient","enrollment":42},{"nctId":"NCT01828970","phase":"PHASE4","title":"Pilot Study of Glycemic Control in Diabetic Hemodialyzed Patients","status":"COMPLETED","sponsor":"Centre Europeen d'Etude du Diabete","startDate":"2010-01","conditions":"Diabetes Mellitus","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":143,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Basal insulin analogues","genericName":"Basal insulin analogues","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Basal insulin analogues are long-acting insulin formulations that bind to insulin receptors to promote glucose uptake and utilization, providing steady background insulin coverage for blood glucose control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}